Natural Gas Services Group, Inc. (NGS)

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases,.

Natural Gas Services Group, Inc. enjoys strong revenue growth and expanding margins driven by robust demand in core markets. Management's guidance for the next quarter signals continued momentum, supported by potential growth drivers and operational efficiencies. Valuation remains acceptable despite the sharp price increase from previous years considering potential catalysts.

The average of price targets set by Wall Street analysts indicates a potential upside of 38.6% in Natural Gas Services (NGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PANW delivered strong Q4 results, beating on revenue and EPS, and raised FY26 guidance, highlighting robust NGS and platformization momentum. The $25B CyberArk acquisition is a strategic move to capitalize on surging identity security demand in the AI era, further strengthening PANW's portfolio. Monte Carlo simulations suggest a near 100% chance PANW will exceed FY26 EPS guidance, supporting my $239 price target and continued BUY rating.

Natural Gas Services (NGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 41.7% upside potential for Natural Gas Services (NGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Lower equipment demand and conservative capital spending by upstream players make the outlook for the Zacks Oil and Gas- Mechanical and Equipment industry gloomy. NGS, SEI and OIS are trying to survive industry challenges.

Natural Gas Services Group, Inc. (NYSE:NGS ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Anna Delgado - Corporate Participant Investor Relations Coordinator - Corporate Participant Ian M. Eckert - Chief Financial Officer Justin C.

Natural Gas Services (NGS) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.34 per share a year ago.

Midland, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced financial results for the three months ended June 30, 2025. The Company also provided updated guidance today, increasing both the low- and high-end of its full-year 2025 Adjusted EBITDA guidance to $76 - $80 million (from $74 - $79 million), citing continued strength in its business and contracted large horsepower unit deployments in the second half of 2025.

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epi.

Midland, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE: NGS), (“NGS” or the “Company”), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that its Board of Directors has declared the first-ever quarterly cash dividend of $0.10 per share of common stock, or $0.40 per share of common stock on an annualized basis. This cash dividend will be paid on August 22, 2025 to all stockholders of record as of the close of business on August 8, 2025.

VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions. This new offering strengthens QIAGEN's position as a provider of differentiated solutions for use on any next-generation sequencing (NGS) platforms spanning both short- and long-read technologies. The new QIAGEN panels are optim.

KNOP, NGS and PENG made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 14, 2025.

NGS, ASC, ATGE and RGCO boast strong net margins, rising earnings and bullish analyst ratings that signal upside.

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to.